Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
31/08/2026 02:57
BRIEF-Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211 Aug 31 (Reuters) - Abbisko Cayman Limited 2256.HK:
THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN PHASE I TRIAL OF ABSK211
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration